<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00117130</url>
  </required_header>
  <id_info>
    <org_study_id>20020147</org_study_id>
    <nct_id>NCT00117130</nct_id>
  </id_info>
  <brief_title>Study to Evaluate Effectiveness of Aranesp®</brief_title>
  <official_title>Aranesp® Monthly Preference Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <brief_summary>
    <textblock>
      The purpose of this study was to evaluate subject preference for Aranesp® administered once
      monthly (i.e., every 4 weeks (Q4W)) or Procrit® administered once weekly (QW).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Subject preference</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Subject productivity and subject selection of Aranesp® or Procrit® therapy in the parallel arm portion and at study conclusion.</measure>
  </secondary_outcome>
  <condition>Kidney Disease</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aranesp®</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: - Subjects must have signed written informed consent - Be on Procrit®
        QW or Q2W for a minimum of 12 weeks - Must currently be on a stable dose of Procrit®
        (defined as less than 25% change in Procrit® dose over the 4 week period immediately prior
        to enrollment, with no missed doses) - Have Hgb 10-12 g/dL for at least 4 weeks prior to
        study start - Have 15 less than GFR less than 89 mL/min/1.73 m2 - Have serum vitamin B12
        and folate levels above the lower limits of normal - Transferrin saturation greater than
        20% Exclusion Criteria: - Currently receiving investigational erythropoietic agents -
        Expected to initiate renal replacement therapy (dialysis or transplantation) within 1 year
        of study start - Have less than 1 year life expectancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <link>
    <url>http://www.aranesp.com/</url>
    <description>FDA-approved Drug Labeling</description>
  </link>
  <verification_date>January 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 30, 2005</study_first_submitted>
  <study_first_submitted_qc>June 30, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 4, 2005</study_first_posted>
  <last_update_submitted>January 20, 2011</last_update_submitted>
  <last_update_submitted_qc>January 20, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 21, 2011</last_update_posted>
  <responsible_party>
    <name_title>Global Development Leader</name_title>
    <organization>Amgen Inc.</organization>
  </responsible_party>
  <keyword>Kidney disease, Renal, CKD (Chronic Kidney Disease)</keyword>
  <keyword>CRI (Chronic Renal Insufficiency), Pre-dialysis, Amgen</keyword>
  <keyword>Aranesp®, Darbepoetin alfa, QW dosing</keyword>
  <keyword>Q2W dosing, Q4W dosing</keyword>
  <keyword>Patient preference, Subject preference</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Darbepoetin alfa</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

